Signed in as:
filler@godaddy.com
Precision early cancer screening
Early cancer genetic testing is the use of molecular biology techniques to detect changes in cancer-related genes or markers in order to detect signs of cancer or precancerous lesions as early as possible. These testing can be performed by detecting mutations in specific genes, changes in the expression levels of certain genes, or specific tumor markers.
Early cancer testing has become a standard for precision cancer treatment in developed countries. Scientists can first determine whether an individual carries cancer cells through screening, and then carry out precision medicine based on the number of cancer cells and progression of tumors.
In the treatment, cancer patients typically choose chemotherapy drugs based on pathologic classification. With genetic testing, which can discover mutations, we can develop more effective chemotherapy, targeted therapy, and immunotherapy with fewer side effects. In addition, we can assess the risk of cancer among family members.
EBOVIR conducts accurate early cancer genetic screening based on digital PCR technology, which can screen for nearly 100 mutations in up to 17 cancer genes, guaranteeing 99.99% accuracy, with specific genetic testing services listed as follows:
B1: Precise probe-based early screening using digital PCR technology for nearly 100 mutations in up to 17 cancer genes, providing accurate health screening reports, which can screen for cancer genes and cancers as shown in the early screening list.
B2: To provide accurate probe-based early screening for a particular cancer using digital PCR technology, and the cancers that can be screened are shown in the Early Screening List.
Next-Generation Biotech Innovations
Why we do the cancer cfDNA surveillance with our dqPCR technology
In the realm of oncology, early detection and continuous monitoring of cancer are critical for successful treatment outcomes. Our advanced detection platform leverages circulating free DNA (cfDNA) as biomarkers, offering a significant leap over traditional cancer detection methods.
Traditional cancer diagnostics often rely on imaging and tissue biopsies, which have limitations in sensitivity, especially for detecting early-stage disease or monitoring for minimal residual disease post-treatment. In contrast, our technology employs digital PCR (dpPCR) to detect cfDNA with unparalleled precision. The dpPCR amplifies and quantifies specific DNA sequences, allowing for the detection of rare genetic material that is characteristic of cancer cells, even at very low levels, at really early stage of cancer occurs or lower cancer cells exsit.
The graph we present visualizes this advantage: even in the post-treatment, doctors sign the patient as " Cancer free", cfDNA levels plummet, suggesting a reduction in tumor burden. Yet, the sensitivity of dpPCR can reveal subtle increases in cfDNA, potentially flagging early signs of cancer recurrence well before traditional methods would identify them. This enhanced sensitivity is pivotal not only for early detection but also for monitoring patients during the so-called 'cancer-free' intervals. Our dpPCR technology can therefore provide a more accurate reflection of the patient’s disease status.
By integrating our dpPCR-based cfDNA surveillance into early cancer screening and clinical practice, we offer oncologists a powerful tool for real-time, non-invasive tumor tracking. This technological advancement stands to transform patient care by enabling earlier therapeutic intervention and more informed clinical decision-making.
more and more cancer genes cf-DNA can be detected
Associated cancers as shown here
General digital qPCR (dqPCR) workflow in cancer liquid biopsies
Figure adapted from Diagnostics 2022, 12(12), 3042; https://doi.org/10.3390/diagnostics12123042